High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial

Marina J Harutyunyan; Anders B Mathiasen; Per Winkel; Jens P Gøtze; Jørgen Fischer Hansen; Per Hildebrandt; Gorm Boje Jensen; Jørgen Hilden; Christian M Jespersen; Erik Kjøller; Hans J Kolmos; Christian Gluud; Jens Kastrup; CLARICOR Trial Group

doi:10.3109/00365513.2010.538081

High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial

Marina J Harutyunyan, Anders B Mathiasen, Per Winkel, Jens P Gøtze, Jørgen Fischer Hansen, Per Hildebrandt, Gorm Boje Jensen, Jørgen Hilden, Christian M Jespersen, Erik Kjøller, Hans J Kolmos, Christian Gluud, Jens Kastrup, CLARICOR Trial Group

Section of Biostatistics

27 Citations (Scopus)

Abstract

Background. Patients with stable coronary artery disease (CAD) have a poor prognosis. The aim of the study was to evaluate the extent to which serum high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurement alone or together could be prognostic biomarkers in patients with stable CAD. Materials and methods. During the 2.6-year follow-up period 270 patients among the 4264 patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 cardiovascular deaths (CVD)). Results. Serum NT-proBNP was significantly associated with MI (hazard ratio (HR), 1. 65 (refers to a 2.72 fold increase in serum level, p = 0.0005), CVD (HR, 2.42, p < 0.0005) and non-CVD (HR, 1.79, p < 0.0005). When correcting for hs-CRP, NT-proBNP was still significantly associated with MI (HR, 1.63, p = 0.0005), CVD (HR, 2.36, p < 0.0005) and non-CVD (HR, 1.66, p < 0.0005). Serum hs-CRP was compared to NT-proBNP less associated with MI (HR, 1.20, p = 0.001), CVD (HR, 1.39, p < 0.0005) and non-CVD (HR, 1.67, p < 0.0005). When corrected for NT-proBNP, hs-CRP was only associated with non-CVD (HR, 1.51, p < 0.0005). When adjusting for cardiovascular risk factors hs-CRP predicted non-CVD (HR, 1.46) and all-cause death (HR, 1.24) and NT-proBNP predicted MI (HR, 1.50), CVD (HR, 1.98), non-CVD (HR, 1.39), and all-cause death (HR, 1.62)(p < 0.0005 for all). Conclusion. Increased serum NT-proBNP was a stronger predictor of MI, cardiovascular death and non-cardiovascular death than hs-CRP in patients with stable CAD. Once NT-proBNP was taken into account, hs-CRP did not improve predictions.

Original language	English
Journal	Scandinavian Journal of Clinical & Laboratory Investigation
Volume	71
Issue number	1
Pages (from-to)	52-62
Number of pages	11
ISSN	0036-5513
DOIs	https://doi.org/10.3109/00365513.2010.538081
Publication status	Published - 1 Feb 2011

Access to Document

10.3109/00365513.2010.538081

Cite this

Harutyunyan, M. J., Mathiasen, A. B., Winkel, P., Gøtze, J. P., Hansen, J. F., Hildebrandt, P., Jensen, G. B., Hilden, J., Jespersen, C. M., Kjøller, E., Kolmos, H. J., Gluud, C., Kastrup, J., & CLARICOR Trial Group (2011). High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. Scandinavian Journal of Clinical & Laboratory Investigation, 71(1), 52-62. https://doi.org/10.3109/00365513.2010.538081

High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. / Harutyunyan, Marina J; Mathiasen, Anders B; Winkel, Per et al.

In: Scandinavian Journal of Clinical & Laboratory Investigation, Vol. 71, No. 1, 01.02.2011, p. 52-62.

Research output: Contribution to journal › Journal article › Research › peer-review

Harutyunyan, MJ, Mathiasen, AB, Winkel, P, Gøtze, JP, Hansen, JF, Hildebrandt, P, Jensen, GB, Hilden, J, Jespersen, CM, Kjøller, E, Kolmos, HJ, Gluud, C, Kastrup, J & CLARICOR Trial Group 2011, 'High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial', Scandinavian Journal of Clinical & Laboratory Investigation, vol. 71, no. 1, pp. 52-62. https://doi.org/10.3109/00365513.2010.538081

Harutyunyan MJ, Mathiasen AB, Winkel P, Gøtze JP, Hansen JF, Hildebrandt P et al. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. Scandinavian Journal of Clinical & Laboratory Investigation. 2011 Feb 1;71(1):52-62. doi: 10.3109/00365513.2010.538081

@article{f91f80d4480048c8b5d03b5f93a7ca5c,

title = "High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial",

abstract = "Background. Patients with stable coronary artery disease (CAD) have a poor prognosis. The aim of the study was to evaluate the extent to which serum high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurement alone or together could be prognostic biomarkers in patients with stable CAD. Materials and methods. During the 2.6-year follow-up period 270 patients among the 4264 patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 cardiovascular deaths (CVD)). Results. Serum NT-proBNP was significantly associated with MI (hazard ratio (HR), 1. 65 (refers to a 2.72 fold increase in serum level, p = 0.0005), CVD (HR, 2.42, p < 0.0005) and non-CVD (HR, 1.79, p < 0.0005). When correcting for hs-CRP, NT-proBNP was still significantly associated with MI (HR, 1.63, p = 0.0005), CVD (HR, 2.36, p < 0.0005) and non-CVD (HR, 1.66, p < 0.0005). Serum hs-CRP was compared to NT-proBNP less associated with MI (HR, 1.20, p = 0.001), CVD (HR, 1.39, p < 0.0005) and non-CVD (HR, 1.67, p < 0.0005). When corrected for NT-proBNP, hs-CRP was only associated with non-CVD (HR, 1.51, p < 0.0005). When adjusting for cardiovascular risk factors hs-CRP predicted non-CVD (HR, 1.46) and all-cause death (HR, 1.24) and NT-proBNP predicted MI (HR, 1.50), CVD (HR, 1.98), non-CVD (HR, 1.39), and all-cause death (HR, 1.62)(p < 0.0005 for all). Conclusion. Increased serum NT-proBNP was a stronger predictor of MI, cardiovascular death and non-cardiovascular death than hs-CRP in patients with stable CAD. Once NT-proBNP was taken into account, hs-CRP did not improve predictions.",

author = "Harutyunyan, {Marina J} and Mathiasen, {Anders B} and Per Winkel and G{\o}tze, {Jens P} and Hansen, {J{\o}rgen Fischer} and Per Hildebrandt and Jensen, {Gorm Boje} and J{\o}rgen Hilden and Jespersen, {Christian M} and Erik Kj{\o}ller and Kolmos, {Hans J} and Christian Gluud and Jens Kastrup and {CLARICOR Trial Group}",

year = "2011",

month = feb,

day = "1",

doi = "10.3109/00365513.2010.538081",

language = "English",

volume = "71",

pages = "52--62",

journal = "Scandinavian Journal of Clinical & Laboratory Investigation",

issn = "0036-5513",

publisher = "Taylor & Francis",

number = "1",

}

TY - JOUR

T1 - High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial

AU - Harutyunyan, Marina J

AU - Mathiasen, Anders B

AU - Winkel, Per

AU - Gøtze, Jens P

AU - Hansen, Jørgen Fischer

AU - Hildebrandt, Per

AU - Jensen, Gorm Boje

AU - Hilden, Jørgen

AU - Jespersen, Christian M

AU - Kjøller, Erik

AU - Kolmos, Hans J

AU - Gluud, Christian

AU - Kastrup, Jens

AU - CLARICOR Trial Group

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Background. Patients with stable coronary artery disease (CAD) have a poor prognosis. The aim of the study was to evaluate the extent to which serum high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurement alone or together could be prognostic biomarkers in patients with stable CAD. Materials and methods. During the 2.6-year follow-up period 270 patients among the 4264 patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 cardiovascular deaths (CVD)). Results. Serum NT-proBNP was significantly associated with MI (hazard ratio (HR), 1. 65 (refers to a 2.72 fold increase in serum level, p = 0.0005), CVD (HR, 2.42, p < 0.0005) and non-CVD (HR, 1.79, p < 0.0005). When correcting for hs-CRP, NT-proBNP was still significantly associated with MI (HR, 1.63, p = 0.0005), CVD (HR, 2.36, p < 0.0005) and non-CVD (HR, 1.66, p < 0.0005). Serum hs-CRP was compared to NT-proBNP less associated with MI (HR, 1.20, p = 0.001), CVD (HR, 1.39, p < 0.0005) and non-CVD (HR, 1.67, p < 0.0005). When corrected for NT-proBNP, hs-CRP was only associated with non-CVD (HR, 1.51, p < 0.0005). When adjusting for cardiovascular risk factors hs-CRP predicted non-CVD (HR, 1.46) and all-cause death (HR, 1.24) and NT-proBNP predicted MI (HR, 1.50), CVD (HR, 1.98), non-CVD (HR, 1.39), and all-cause death (HR, 1.62)(p < 0.0005 for all). Conclusion. Increased serum NT-proBNP was a stronger predictor of MI, cardiovascular death and non-cardiovascular death than hs-CRP in patients with stable CAD. Once NT-proBNP was taken into account, hs-CRP did not improve predictions.

AB - Background. Patients with stable coronary artery disease (CAD) have a poor prognosis. The aim of the study was to evaluate the extent to which serum high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurement alone or together could be prognostic biomarkers in patients with stable CAD. Materials and methods. During the 2.6-year follow-up period 270 patients among the 4264 patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 cardiovascular deaths (CVD)). Results. Serum NT-proBNP was significantly associated with MI (hazard ratio (HR), 1. 65 (refers to a 2.72 fold increase in serum level, p = 0.0005), CVD (HR, 2.42, p < 0.0005) and non-CVD (HR, 1.79, p < 0.0005). When correcting for hs-CRP, NT-proBNP was still significantly associated with MI (HR, 1.63, p = 0.0005), CVD (HR, 2.36, p < 0.0005) and non-CVD (HR, 1.66, p < 0.0005). Serum hs-CRP was compared to NT-proBNP less associated with MI (HR, 1.20, p = 0.001), CVD (HR, 1.39, p < 0.0005) and non-CVD (HR, 1.67, p < 0.0005). When corrected for NT-proBNP, hs-CRP was only associated with non-CVD (HR, 1.51, p < 0.0005). When adjusting for cardiovascular risk factors hs-CRP predicted non-CVD (HR, 1.46) and all-cause death (HR, 1.24) and NT-proBNP predicted MI (HR, 1.50), CVD (HR, 1.98), non-CVD (HR, 1.39), and all-cause death (HR, 1.62)(p < 0.0005 for all). Conclusion. Increased serum NT-proBNP was a stronger predictor of MI, cardiovascular death and non-cardiovascular death than hs-CRP in patients with stable CAD. Once NT-proBNP was taken into account, hs-CRP did not improve predictions.

U2 - 10.3109/00365513.2010.538081

DO - 10.3109/00365513.2010.538081

M3 - Journal article

SN - 0036-5513

VL - 71

SP - 52

EP - 62

JO - Scandinavian Journal of Clinical & Laboratory Investigation

JF - Scandinavian Journal of Clinical & Laboratory Investigation

IS - 1

ER -

High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial

Abstract

Access to Document

Fingerprint

Cite this